Immunovant
IMVT
32.04
-0.07
-0.22%
Immunovant
US · IMVT
#1790 by market cap
Listed 2017
32.04
-0.07
-0.22%
Live - 5344 symbols - heartbeat 247s ago
· 2026-10-08 08:25
Pre-market
31.31
-2.28%
After-hours
32.04
0.00%
Overnight
30.98
-3.31%
- Market cap
- 6.62B
- P/E (TTM)i
- -11.40
- P/Bi
- 9.00
- EPSi
- -2.77
- Div yieldi
- 0.00%
- 52W posi
- 53%
Reader sentiment
Are you bullish or bearish on IMVT?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Ownership Signal how this is computed
Mixed / stable
- The number of reporting institutions increased by 1 in the most recent period (2026/Q3).
- Total institutional ownership (as a % of shares) was little changed.
Institutional ownership
- Held by institutions
- 108.75% -0.02pp
- Institutions
- 265 +1
- As of
- 2026/Q3 vs. prior period
Ownership vs. money flow
AlignedInstitutions trimmed shares last reporting period, and the stock has seen net outflows in main-fund flow over the last 20 trading sessions - the two line up.
Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.
Holder types
Public Company56.95%
Mutual Fund28.51%
Hedge Fund14.47%
VC/PE Fund7.46%
Private Company0.98%
Individual/Insider0.70%
Insurance Company0.19%
Government Pension Fund0.15%
Top holders as of 2025-12-12
Roivant Sciences Ltd.
54.86% · 113.32M sh
FMR
7.83% · 16.17M sh
Deep Track Capital, LP
4.52% · 9.34M sh
BlackRock
3.48% · 7.18M sh
Farallon Capital Management, L.L.C.
2.81% · 5.81M sh
Baker Bros. Advisors LP
2.63% · 5.44M sh
State Street Global Advisors
2.24% · 4.62M sh
TCG Crossover Management, LLC
2.16% · 4.46M sh
Vanguard Capital Management, LLC
2.03% · 4.20M sh
T. Rowe Price Group, Inc.
1.96% · 4.05M sh
Bar length is relative to the largest holder shown here, not to 100% of the company.
Insiders
50 filings tracked · 23 buys · 27 sells
| Name | Role | Stake |
|---|---|---|
| Roivant Sciences Ltd. | -- | 54.86% |
| Peter Salzmann | Chief Executive Officer | 0.30% |
| William Macias | Chief Medical Officer | 0.10% |
| Eva Barnett | Chief Financial Officer | 0.08% |
| Atul Pande | Independent Director | 0.05% |
| Michael Geffner | Chief Medical Officer | 0.04% |
| Douglas Hughes | Independent Director | 0.03% |
| Jay Stout | Chief Technology Officer | 0.02% |
| Christopher Van Tuyl | Chief Legal Officer | 0.02% |
| Tiago Girao | Chief Financial Officer | 0.02% |
Insider transactions most recent Form 4 filings
| Date | Name | Role | Type | Shares | Price |
|---|---|---|---|---|---|
| 2026-09-22 | Christopher Van Tuyl | Chief Legal Officer | Open Market Disposition | -2,846 | $36.36 |
| 2026-08-27 | Atul Pande | Independent Director | Derivative Exercise and Sale | -1,500 | $8.43–43.27 |
| 2026-08-19 | Melanie Gloria | Chief Operating Officer | Open Market Disposition | -3,056 | $44.16 |
| 2026-07-23 | Atul Pande | Independent Director | Derivative Exercise and Sale | -1,500 | $8.43–39.80 |
| 2026-07-22 | Tiago Girao | Chief Financial Officer | Open Market Disposition | -6,798 | $38.69 |
| 2026-07-22 | Jay Stout | Chief Technology Officer | Open Market Disposition | -2,857 | $38.69 |
| 2026-07-07 | Christopher Van Tuyl | Chief Legal Officer | Open Market Disposition | -1,206 | $39.53–39.99 |
| 2026-07-07 | Melanie Gloria | Chief Operating Officer | Open Market Disposition | -2,036 | $39.53–39.99 |
| 2026-07-07 | Jay Stout | Chief Technology Officer | Open Market Disposition | -3,487 | $39.53–39.99 |
| 2026-07-01 | Eric Venker | Director | Derivative Exercise and Sale | -89,721 | $14.46–38.48 |
| 2026-06-30 | Eric Venker | Director | Derivative Exercise and Retained | +2,467 | $14.46 |
| 2026-06-25 | Atul Pande | Independent Director | Derivative Exercise and Sale | -1,500 | $8.43–38.01 |
| 2026-06-25 | Christopher Van Tuyl | Chief Legal Officer | Derivative Exercise and Sale | -17,824 | $15.20–38.96 |
| 2026-06-25 | Tiago Girao | Chief Financial Officer | Derivative Exercise and Sale | -10,000 | $15.90–38.46 |
| 2026-06-25 | Melanie Gloria | Chief Operating Officer | Open Market Disposition | -17,714 | $38.18–38.95 |
| 2026-06-25 | Jay Stout | Chief Technology Officer | Open Market Disposition | -40,000 | $38.18–38.94 |
| 2026-06-17 | Christopher Van Tuyl | Chief Legal Officer | Open Market Disposition | -2,634 | $35.39 |
| 2026-06-14 | Atul Pande | Independent Director | Derivative Exercise and Sale | -1,500 | $8.43–34.02 |
| 2026-05-27 | Andrew Fromkin | Director | Open Market Disposition | -25,350 | $33.56 |
| 2026-05-27 | Andrew Fromkin | Director | Derivative Exercise and Sale | -196,601 | $4.99–33.56 |
Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.
Quote time 2026-10-08 08:25:11 · For reference only, not investment advice and not tailored to your situation.